In the 1-methyl-4-phenylpyridinium (MPP+) model of Parkinson’s disease, inhibition of PDI or inhibition of ERO1α by EN460 (IC50 of 1.9 μM) can prevent accumulation of α-synuclein and MPP+ neurotoxicity in the ER. This evidence concerns the gene ERO1A and Parkinson disease.